718 related articles for article (PubMed ID: 14697898)
1. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
Magyar K; Szende B
Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
[TBL] [Abstract][Full Text] [Related]
2. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
3. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective and neuronal rescue effects of selegiline: review.
Magyar K; Haberle D
Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
[TBL] [Abstract][Full Text] [Related]
5. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition.
Le W; Jankovic J; Xie W; Kong R; Appel SH
Neurosci Lett; 1997 Mar; 224(3):197-200. PubMed ID: 9131670
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective rather than neurorescue or neurorestorative effect of selegiline against MPTP-induced dopaminergic toxicity.
Wu WR; Zhu XZ; Guan HJ; Wang RG; Ji XQ
Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):146-50. PubMed ID: 10437162
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons.
McKinley ET; Baranowski TC; Blavo DO; Cato C; Doan TN; Rubinstein AL
Brain Res Mol Brain Res; 2005 Nov; 141(2):128-37. PubMed ID: 16209898
[TBL] [Abstract][Full Text] [Related]
8. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.
Klegeris A; McGeer PL
Exp Neurol; 2000 Dec; 166(2):458-64. PubMed ID: 11085911
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective aspects of a novel MAO-B inhibitor PF9601N.
Pérez V; Morón J; Pastó M; Unzeta M
Neurobiology (Bp); 2000; 8(3-4):231-6. PubMed ID: 11225513
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research.
Magyar K; Szende B; Lengyel J; Tekes K
J Neural Transm Suppl; 1996; 48():29-43. PubMed ID: 8988460
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
13. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
Knoll J
Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
[TBL] [Abstract][Full Text] [Related]
14. Neural progenitor cells are protected against MPTP by MAO-B inhibitors.
He XJ; Uetsuka K; Nakayama H
Neurotoxicology; 2008 Nov; 29(6):1141-6. PubMed ID: 18606181
[TBL] [Abstract][Full Text] [Related]
15. The pharmacology of selegiline.
Magyar K
Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanisms of the neuroprotective effect of (-)-deprenyl].
Pálfi M; Szökó E; Kálmán M
Orv Hetil; 2006 Jul; 147(27):1251-7. PubMed ID: 16927880
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
18. [Medicamentous strategy for improving the quality of life in the senescence].
Knoll J
Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
Youdim MB
J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]